Mediwound’s Strategic Growth and Positive Outlook Drive Buy Rating

Analyst Josh Jennings of TD Cowen reiterated a Buy rating on Mediwound (MDWD – Research Report), retaining the price target of $25.00.

Josh Jennings has given his Buy rating due to a combination of factors surrounding Mediwound’s strategic developments and financial projections. One of the key reasons is the increasing adoption of NexoBrid in the US market, which has shown a significant sequential sales increase. This growth is expected to continue as manufacturing capacity expands, addressing the current demand that surpasses production capabilities.
Additionally, the progress of EscharEx’s clinical trials adds to the positive outlook. The Phase III trial for venous leg ulcers (VLU) is advancing, with an interim analysis anticipated in mid-2026, and further studies are planned against competing treatments. Despite a decrease in first-quarter revenue compared to the previous year, the company’s financial guidance remains optimistic, with projected revenue growth in the coming years. These factors combined provide a solid foundation for Jennings’s Buy rating on Mediwound’s stock.

According to TipRanks, Jennings is a 4-star analyst with an average return of 3.6% and a 50.70% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings.